Trials / Completed
CompletedNCT00376090
Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults
A Phase I Double-Blind, Randomized, Dose Escalating, Placebo-Controlled, Study of Safety and Immunogenicity of WRAIR/NIH Live Recombinant MVA-CMDR (HIV-1 CM235 Env/ CM240 Gag/Pol) Administered by Intramuscular (IM) or Intradermal (ID) Route In HIV-Uninfected Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- U.S. Army Medical Research and Development Command · Federal
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the safety and the immune responses to the HIV vaccine candidate, MVA-CMDR. This vaccine was designed to induce immune responses to three HIV "passenger" genes encoded with the viral vector, MVA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MVA-CMDR | 10\^7 PFU IM, 1.0 mL |
| BIOLOGICAL | Placebo | 1.0 mL IM |
| BIOLOGICAL | MVA-CMDR | 10\^6 PFU ID, 0.1 mL |
| BIOLOGICAL | Placebo | 0.1 mL ID |
| BIOLOGICAL | MVA-CMDR | 10\^8 PFU IM, 1.0 mL |
| BIOLOGICAL | MVA-CMDR | 10\^7 PFD ID, 0.1 mL |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2006-09-14
- Last updated
- 2017-10-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00376090. Inclusion in this directory is not an endorsement.